Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum NervGen Pharma Corp V.NGEN

Alternate Symbol(s):  NGENF

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a... see more

TSXV:NGEN - Post Discussion

NervGen Pharma Corp > This has 1,000 bagger potential, article coming next week
View:
Post by Geodan2 on Apr 29, 2022 3:43pm

This has 1,000 bagger potential, article coming next week

 NervGen Regenerates Neurons, What Is A Drug That Reverses Paralysis, MS, Stroke And Alzheimer's Worth? Apr. 23, 2022 7:17 PM ET| About: NervGen Pharma Corp. (NGENF), Includes: KRRGF, PTRUF Darp Research

Summary NervGen has already regenerated neurons under the microscope and in live rats with severed spinal cords. The rats regained most of the function in paralyzed legs.

The market cap of NervGen is under $80 million. It is currently in Phase 1 FDA trials in humans and is about to go into Phase 2.

NervGen has exclusive rights to the technology from Case Western University. It is backed by top experts in the field and staffed by very high level pharma executives. It has no competitors that can repair damage to the nervous system.

If it works 50% as well in humans as in animals, a $15 billion market cap is feasible. It is rare to find drug developer that has an outstanding risk/reward proposition. Most are bad investments that go bankrupt or lose much of their value from my observation. NervGen Phrama, (NGEN.TSX-V)(OTCPK:NGENF) is a big exception to the common overvaluation in this sector.

I have over 75 stocks in my portfolio and NervGen is the only drug company stock in it. The social good possible from their drug is the best have ever seen. Plus the investment potential of the company is also the best have ever seen.

Doing stock research is something I have spent about 25 hours a week doing for the last 20 years. By accident saw a video about them and their drug candidate. After watching the videos below and doing more research on the company, see it as the highest potential stock have ever found. Here is link to 2 videos in article. It is about 10 pages long, hopefully will be out early next week, awaiting one final proof. I am submitting as an article not a blogpost. That is on SeekingAlpha.

https://youtu.be/9paZgPPjn_c+ Very informative interview with CEO A medical doctor was interviewed about NervGen and sees them the same as I do. It is Dr. Mark Swaim, founder of BioPub. He has made it the largest position in his portfolio and says it is the best drug stock investment he has ever seen. That video is below. It is queued to where he talks about NervGen. https://youtu.be/F6WOF0Zprao?t=711+

I have recently sold down to 10% on my Karora position with excellent multi-bagger profit. NervGen is a stock most of the profit has gone into. Talked with the CEO about an hour this week, like how he is running NervGen. Their team is stellar as you will see here: https://nervgen.com/management/ click on the names and you will find it hard to believe the stock is only ay $80 million market cap.

Cheers
Comment by WALLSTREEETHERO on Jun 28, 2023 10:55am
https://finance.yahoo.com/news/nervgen-pharma-receive-more-us-123000753.html
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities